ZONIPORIDE DIHYDROCHLORIDE

The Uses of ZONIPORIDE DIHYDROCHLORIDE

Zoniporide Dihydrochloride, is a potent and selective inhibitor of human sodium-hydrogen exchanger isoform1(NHE-1) and protects against cardiac ischemia-reperfusion injury.

The Uses of ZONIPORIDE DIHYDROCHLORIDE

The sodium-hydrogen exchanger isoform-1 (NHE-1) is the most predominant isoform of the Na+/H+ exchanger and is expressed in the heart where it contributes to cardiomyocyte pH homeostasis. It plays an important role in the myocardial response to ischemia-reperfusion. Zoniporide inhibits human NHE-1 with an IC50 value of 14 nM, displaying greater than 150-fold selectivity over other NHE isoforms. It has been shown to reduce infarct size in a rabbit myocardial ischemia-reperfusion model without adversely affecting hemodynamics or cardiac function. In isolated heart, zoniporide reduced infarct size with an EC50 value of 0.25 nM.

The Uses of ZONIPORIDE DIHYDROCHLORIDE

Zoniporide is a potent and selective inhibitor of human sodium-hydrogen exchanger isoform1(NHE-1) and protects against cardiac ischemia-reperfusion injury.

Biological Activity

zoniporide (hydrochloride) is a novel, potent, and selective sodium-hydrogen exchanger isoform-1 (nhe-1) inhibitor [1]. the na+/h+ exchanger (nhe) has been involved in intracellular ph homeostasis of many mammalian cell types. until now, seven nhe isoforms (nhe1–nhe7) have been identified. nhe1 is the most predominant isoform expressed in heart responsible for maintaining cardiomyocyte ph homeostasis. activation of nhe is essential for the restoration of physiological ph. hyperactivation of nhe1 during ischemia–reperfusion episodes disrupts the intracellular ion balance, leading to cardiac dysfunction and damage [2].

in vitro

zoniporide inhibited human nhe-1 with an ic50 of 14 nm, showed >150-fold selectivity against other nhe isoforms, and potently inhibited ex vivo nhe-1-dependent swelling of human platelets. in the isolated heart (langendorff), zoniporide dose-dependently reduced infarct size with an ec50 of 0.25 nm. zoniporide at 50 nm reduced infarct size by 83% [1].

in vivo

zoniporide was well tolerated in preclinical animal models, exhibited moderate plasma protein binding with t1/2 of 1.5 h in monkeys. in rabbit models of myocardial ischemia-reperfusion injury, zoniporide significantly reduced infarct size without adverse effects. in open chest, anesthetized rabbits, zoniporide reduced infarct size in a dose-dependent manner with an ed50 of 0.45 mg/kg/h. zoniporide also inhibited nhe-1-mediated platelet swelling. zoniporide attenuated postischemic cardiac contractile dysfunction in conscious primates, and reduced both the incidence and duration of ischemiareperfusion-induced ventricular fibrillation in rats [1].

References

[1] tracey w r, allen m c, frazier d e, et al. zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (nhe-1)[j]. cardiovascular drug reviews, 2003, 21(1): 17-32.
[2] masereel b, pochet l, laeckmann d. an overview of inhibitors of na+/h+ exchanger[j]. european journal of medicinal chemistry, 2003, 38(6): 547-554.